v3.26.1
Accounts payable and accrued liabilities
 6 Months Ended
Jun. 30, 2026
Payables and Accruals [Abstract]  
Accounts payable and accrued liabilities Accounts payable and accrued liabilities
Accounts payable and accrued liabilities were comprised of the following:
June 30, 2026December 31, 2025
(in thousands)
Trade accounts payable$373 $1,173 
Research and development accruals448 412 
Professional fee accruals735 1,075 
Payroll accruals1,134 2,159 
Restructuring liabilities160 640 
Total accounts payable and accrued liabilities$2,850 $5,459 
In March 2025, the Company implemented changes to focus its efforts on advancing the clinical development of imdusiran and AB-101. The decision was made to exit the Company’s corporate headquarters in Warminster, Pennsylvania, implement workforce reductions and discontinue in-house scientific research. The Company recognized $12.9 million of restructuring charges in 2025, of which there was an aggregate of $0.2 million in medical benefit costs and lease expenses accrued as of June 30, 2026.